ArticleBMJ neurology open2026
Plasma CHI3L1 as a marker of cognitive and structural brain changes in radiologically isolated syndrome.
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The multi-dimensional spectrum of radiologically isolated syndrome: a systematic review of cognitive and psychosocial evidence.Acta neurologica Belgica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiologically isolated syndrome (RIS) is characterised by incidental MRI findings suggestive of multiple sclerosis (MS) in individuals without typical MS symptoms. People with RIS (pwRIS) may have subtle manifestations, including cognitive impairment. We aimed to examine whether plasma chitinase 3-like 1 (pCHI3L1) levels in pwRIS are associated with cognitive impairment and grey matter volumes in regions known to be vulnerable in MS. Methods: We conducted a cross-sectional analysis of 45 individuals with pwRIS and 21 healthy controls. Cognitive performance was assessed with the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery, and global cognitive impairment was defined as failure on two or more MACFIMS subtests. Plasma CHI3L1 levels were measured using the Ella microfluidics system, and concentrations were natural log-transformed to reduce skewness. Results: Higher log-pCHI3L1 levels were inversely correlated with hippocampal volume (R² = 0.1360, p=0.01) and thalamic volume (R² = 0.1265, p=0.02). pwRIS with global cognitive impairment had higher log-pCHI3L1 levels (p=0.03). Associations were also observed between log-pCHI3L1 levels and design fluency switching (R² = 0.1365, p=0.01) as well as executive function (R² = 0.1636, p=0.01). Conclusions: Log-pCHI3L1 levels were associated with cognitive impairment, hippocampal volume and thalamic volume in pwRIS. These results suggest that pCHI3L1 may represent a blood biomarker of cognitive dysfunction and neurodegeneration in RIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.